These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 30359371)

  • 1. N-substituted phenylbenzamides of the niclosamide chemotype attenuate obesity related changes in high fat diet fed mice.
    Bhagat HA; Compton SA; Musso DL; Laudeman CP; Jackson KMP; Yi NY; Nierobisz LS; Forsberg L; Brenman JE; Sexton JZ
    PLoS One; 2018; 13(10):e0204605. PubMed ID: 30359371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niclosamide piperazine prevents high-fat diet-induced obesity and diabetic symptoms in mice.
    Guo J; Tao H; Alasadi A; Huang Q; Jin S
    Eat Weight Disord; 2019 Feb; 24(1):91-96. PubMed ID: 28780747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel and selective melanin-concentrating hormone receptor 1 antagonist ameliorates obesity and hepatic steatosis in diet-induced obese rodent models.
    Kawata Y; Okuda S; Hotta N; Igawa H; Takahashi M; Ikoma M; Kasai S; Ando A; Satomi Y; Nishida M; Nakayama M; Yamamoto S; Nagisa Y; Takekawa S
    Eur J Pharmacol; 2017 Feb; 796():45-53. PubMed ID: 27986627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repositioning of niclosamide ethanolamine (NEN), an anthelmintic drug, for the treatment of lipotoxicity.
    Park JS; Lee YS; Lee DH; Bae SH
    Free Radic Biol Med; 2019 Jun; 137():143-157. PubMed ID: 31035006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
    Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
    J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation by Tetrahydrocurcumin of Adiposity and Hepatic Steatosis in Mice with High-Fat-Diet-Induced Obesity.
    Pan MH; Chen JW; Kong ZL; Wu JC; Ho CT; Lai CS
    J Agric Food Chem; 2018 Dec; 66(48):12685-12695. PubMed ID: 30415544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Grape pomace reduces the severity of non-alcoholic hepatic steatosis and the development of steatohepatitis by improving insulin sensitivity and reducing ectopic fat deposition in mice.
    Daniel T; Ben-Shachar M; Drori E; Hamad S; Permyakova A; Ben-Cnaan E; Tam J; Kerem Z; Rosenzweig T
    J Nutr Biochem; 2021 Dec; 98():108867. PubMed ID: 34571189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celastrol ameliorates liver metabolic damage caused by a high-fat diet through Sirt1.
    Zhang Y; Geng C; Liu X; Li M; Gao M; Liu X; Fang F; Chang Y
    Mol Metab; 2017 Jan; 6(1):138-147. PubMed ID: 28123944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
    Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
    Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salicornia Extract Ameliorates Salt-Induced Aggravation of Nonalcoholic Fatty Liver Disease in Obese Mice Fed a High-Fat Diet.
    Kim JH; Suk S; Jang WJ; Lee CH; Kim JE; Park JK; Kweon MH; Kim JH; Lee KW
    J Food Sci; 2017 Jul; 82(7):1765-1774. PubMed ID: 28608557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice.
    Takahara I; Akazawa Y; Tabuchi M; Matsuda K; Miyaaki H; Kido Y; Kanda Y; Taura N; Ohnita K; Takeshima F; Sakai Y; Eguchi S; Nakashima M; Nakao K
    PLoS One; 2017; 12(3):e0170591. PubMed ID: 28278289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte-specific PKCβ deficiency protects against high-fat diet-induced nonalcoholic hepatic steatosis.
    Shu Y; Hassan F; Coppola V; Baskin KK; Han X; Mehta NK; Ostrowski MC; Mehta KD
    Mol Metab; 2021 Feb; 44():101133. PubMed ID: 33271332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theobromine ameliorates nonalcoholic fatty liver disease by regulating hepatic lipid metabolism via mTOR signaling pathway in vivo and in vitro.
    Wei D; Wu S; Liu J; Zhang X; Guan X; Gao L; Xu Z
    Can J Physiol Pharmacol; 2021 Aug; 99(8):775-785. PubMed ID: 33290156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122.
    Chai C; Cox B; Yaish D; Gross D; Rosenberg N; Amblard F; Shemuelian Z; Gefen M; Korach A; Tirosh O; Lanton T; Link H; Tam J; Permyakova A; Ozhan G; Citrin J; Liao H; Tannous M; Hahn M; Axelrod J; Arretxe E; Alonso C; Martinez-Arranz I; Betés PO; Safadi R; Salhab A; Amer J; Tber Z; Mengshetti S; Giladi H; Schinazi RF; Galun E
    Gastroenterology; 2020 Sep; 159(3):999-1014.e9. PubMed ID: 32450149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ugonin J improves metabolic disorder and ameliorates nonalcoholic fatty liver disease by regulating the AMPK/AKT signaling pathway.
    Chang TC; Chiou WC; Lai WH; Huang HC; Huang YL; Liu HK; Liang YC; Huang C
    Pharmacol Res; 2021 Jan; 163():105298. PubMed ID: 33220422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lycium barbarum polysaccharides therapeutically improve hepatic functions in non-alcoholic steatohepatitis rats and cellular steatosis model.
    Xiao J; Xing F; Huo J; Fung ML; Liong EC; Ching YP; Xu A; Chang RC; So KF; Tipoe GL
    Sci Rep; 2014 Jul; 4():5587. PubMed ID: 24998389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic phenotype and adipose and liver features in a high-fat Western diet-induced mouse model of obesity-linked NAFLD.
    Luo Y; Burrington CM; Graff EC; Zhang J; Judd RL; Suksaranjit P; Kaewpoowat Q; Davenport SK; O'Neill AM; Greene MW
    Am J Physiol Endocrinol Metab; 2016 Mar; 310(6):E418-39. PubMed ID: 26670487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.
    Orime K; Shirakawa J; Togashi Y; Tajima K; Inoue H; Nagashima Y; Terauchi Y
    Eur J Pharmacol; 2016 Feb; 772():22-32. PubMed ID: 26724391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
    Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
    J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.